Pharmacokinetic evaluation of lanreotide

Bibliography

• Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009;119:3189-202
   PubMed Web of Science ®Google Scholar
• Chanson P, Salenave S, Kamenicky P, Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 2009;6:555-74
   Google Scholar
• Melmed S. Acromegaly. N Engl J Med 1990;322:966-77
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41
   PubMedGoogle Scholar
• Daly AF, Rixhon M, Adam C, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-75
   PubMed Web of Science ®Google Scholar
• Schneider HJ, Sievers C, Saller B, High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 2008;69:432-5
   PubMed Web of Science ®Google Scholar
• Nachtigall L, Delgado A, Swearingen B, Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 2008;93:2035-41
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:61-7
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159:89-95
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva F, Cavagnini F, Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-40
   PubMed Web of Science ®Google Scholar
• Ferone D, Colao A, van der Lely AJ, Lamberts SW. Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs Aging 2000;17:81-92
   PubMed Web of Science ®Google Scholar
• Muller AF, Van Der Lely AJ. Pharmacological therapy for acromegaly: a critical review. Drugs 2004;64:1817-38
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Biermasz NR, Pereira AM, Romijn JA. Therapeutic options in the management of acromegaly: focus on lanreotide Autogel. Biologics 2008;2:463-79
   PubMedGoogle Scholar
• Reichlin S. Secretion of somatostatin and its physiologic function. J Lab Clin Med 1987;109:320-6
   PubMedGoogle Scholar
• Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 1988;9:417-36
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Scott LJ. Lanreotide Autogel: a review of its use in the management of acromegaly. Drugs 2008;68:711-23
   PubMed Web of Science ®Google Scholar
• Danila DC, Haidar JN, Zhang X, Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 2001;86:2976-81
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47
   PubMed Web of Science ®Google Scholar
• Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008;93:2957-68
   PubMed Web of Science ®Google Scholar
• Zatelli MC, degli Uberti E. The significance of new somatostatin analogs as therapeutic agents. Curr Opin Investig Drugs 2009;10:1025-31
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Melmed S. Pasireotide – a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs 2007;10:885-95
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase ii trial. J Clin Endocrinol Metab 2010;95:2781-9
   PubMed Web of Science ®Google Scholar
• Debono M, Newell-Price J. New formulations and approaches in the medical treatment of acromegaly. Curr Opin Endocrinol Diabetes Obes 2010;17:350-5
   PubMed Web of Science ®Google Scholar
• Kumar SS, Ayuk J, Murray RD. Current therapy and drug pipeline for the treatment of patients with acromegaly. Adv Ther 2009;26:383-403
   PubMed Web of Science ®Google Scholar
• Castinetti F, Saveanu A, Morange I, Brue T. Lanreotide for the treatment of acromegaly. Adv Ther 2009;26:600-12
   PubMed Web of Science ®Google Scholar
• Valery C, Pouget E, Pandit A, Molecular origin of the self-assembly of lanreotide into nanotubes: a mutational approach. Biophys J 2008;94:1782-95
   PubMed Web of Science ®Google Scholar
• Bevan JS, Newell-Price J, Wass JA, Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 2008;68:343-9
   PubMed Web of Science ®Google Scholar
• Somatuline Depot (lanreotide) injection US prescribing information. Ipsen Pharma Biotech; 2007
   Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-73
   PubMed Web of Science ®Google Scholar
• Amato G, Mazziotti G, Rotondi M, Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002;56:65-71
   PubMed Web of Science ®Google Scholar
• Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:1856-63
   PubMed Web of Science ®Google Scholar
• Melmed S, Colao A, Barkan A, Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94:1509-17
   PubMed Web of Science ®Google Scholar
• Colao A, Filippella M, Di Somma C, Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine 2003;20:279-83
   PubMed Web of Science ®Google Scholar
• Colao A, Faggiano A, Pivonello R. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. Prog Brain Res 2010;182:281-94
   PubMed Web of Science ®Google Scholar
• Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 2010;29:19
   PubMed Web of Science ®Google Scholar
• Beck-Peccoz P, Persani L, Mannavola D, Campi I. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:597-606
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-88
   PubMed Web of Science ®Google Scholar
• Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci 2008;53:2359-65
   PubMed Web of Science ®Google Scholar
• van Keimpema L, Nevens F, Vanslembrouck R, Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009;137:1661-8 e1-2
   PubMed Web of Science ®Google Scholar
• Hogan MC, Masyuk TV, Page LJ, Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21:1052-61
   PubMed Web of Science ®Google Scholar
• Foxx-Orenstein A, Camilleri M, Stephens D, Burton D. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003;52:1555-61
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94:1500-8
   PubMed Web of Science ®Google Scholar
• Kuhn JM, Basin C, Mollard M, Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014. Eur J Clin Pharmacol 1993;45:73-7
   PubMed Web of Science ®Google Scholar
• Antonijoan RM, Barbanoj MJ, Cordero JA, Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2004;56:471-6
   PubMed Web of Science ®Google Scholar
• Drewe J, Sieber CC, Mottet C, Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers. Clin Pharmacol Ther 1999;65:413-19
   PubMed Web of Science ®Google Scholar
• Sieber CC, Beglinger C, Bart S, Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion. Clin Pharmacol Ther 2004;75:70-9
   PubMed Web of Science ®Google Scholar
• Barbanoj M, Antonijoan R, Morte A, Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. Clin Pharmacol Ther 1999;66:485-91
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Thomas NG, Lan IW, Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency. Clin Pharmacokinet 2006;45:1003-11
   PubMed Web of Science ®Google Scholar
• Kuhn JM, Legrand A, Ruiz JM, Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994;38:213-19
   PubMed Web of Science ®Google Scholar
• Heron I, Thomas F, Dero M, Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721-7
   PubMed Web of Science ®Google Scholar
• Kuhn JM, Arlot S, Lefebvre H, Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000;85:1487-91
   PubMed Web of Science ®Google Scholar
• Astruc B, Marbach P, Bouterfa H, Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45:836-44
   PubMed Web of Science ®Google Scholar
• Troconiz IF, Cendros JM, Peraire C, Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet 2009;48:51-62
   PubMed Web of Science ®Google Scholar
• Caron P. Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients. Ann Endocrinol (Paris) 2002;63:2S19-24
   PubMedGoogle Scholar
• Bronstein M, Musolino N, Jallad R, Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 2005;63:514-19
   PubMed Web of Science ®Google Scholar
• Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism 2005;54:1276-81
   PubMed Web of Science ®Google Scholar
• Feelders RA, Hofland LJ, van Aken MO, Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 2009;69:2207-26
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010;13:60-7
   PubMed Web of Science ®Google Scholar
• Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009;25:2989-99
   PubMed Web of Science ®Google Scholar
• Maiza JC, Vezzosi D, Matta M, Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007;67:282-9
   PubMed Web of Science ®Google Scholar
• Caron P, Bex M, Cullen DR, One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 2004;60:734-40
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H, A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66:859-68
   PubMed Web of Science ®Google Scholar
• Melmed S, Cook D, Schopohl J, Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010;13:18-28
   PubMed Web of Science ®Google Scholar
• Lombardi G, Minuto F, Tamburrano G, Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 2009;32:202-9
   PubMed Web of Science ®Google Scholar
• Resmini E, Dadati P, Ravetti JL, Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007;92:1592-9
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Rebora A, Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 2009;71:237-45
   PubMed Web of Science ®Google Scholar
• Resmini E, Murialdo G, Giusti M, Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. J Endocrinol Invest 2005;28:166-9
   PubMed Web of Science ®Google Scholar
• Livadas S, Hadjidakis DJ, Argyropoulou MI, Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Hormones (Athens) 2006;5:57-63
   PubMedGoogle Scholar
• Auriemma RS, Galdiero M, Grasso LF, Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. Eur J Endocrinol 2010;162:993-9
   PubMed Web of Science ®Google Scholar
• Kelly P, Maher KT, Chew SL, A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. Endocr Pract 2010;16:191-7
   PubMed Web of Science ®Google Scholar
• Salvatori R, Nachtigall LB, Cook DM, Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary 2010;13:115-22
   PubMed Web of Science ®Google Scholar
• Mao ZG, Zhu YH, Tang HL, Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 2010;162:661-6
   PubMed Web of Science ®Google Scholar
• O'Toole D, Ducreux M, Bommelaer G, Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-6
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63
   PubMed Web of Science ®Google Scholar
• Colao A, Martino E, Cappabianca P, First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 2006;29:1017-20
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Lund-Johansen M, Schreiner T, Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008;93:2984-90
   PubMed Web of Science ®Google Scholar
• Caron P, Beckers A, Cullen DR, Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:99-104
   PubMed Web of Science ®Google Scholar
• Chanson P, Borson-Chazot F, Kuhn JM, Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 2008;69:299-305
   PubMed Web of Science ®Google Scholar
• Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 2006;65:320-6
   PubMed Web of Science ®Google Scholar